

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Rigdon Lentz

Serial No.: 09/699,003

Art Unit: 3772

Filed: October 26, 2000

Examiner: P. Bianco

For: *METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449, and copies of the two (2) documents cited therein. This application is allowable and is currently suspended due to an interference in related application U.S.S.N. 09/709,045 at the Board of Patent Appeals and Interferences.

This Supplemental Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(d) after a Notice of Appeal. The Commissioner is hereby authorized to charge \$180.00, the fee set forth under 37 C.F.R. § 1.17(p), to Account No. 50-3129. It is believed that no additional fee is required with this submission. However, should an additional fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1329.

Certification Under 37 C.F.R. §1.97 (e)(2)

Each item of information listed below this certification in this Supplemental Information Disclosure Statement was not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, each item listed below was not known to any individual designated in § 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
6,866,846	03-15-2005	Heinrich, et al.	424/140.1

Publications

HOLOHAN, et al. "Regression of canine mammary carcinoma after immunoadsorption therapy," *Cancer Res.* 42(9):3663-8(1982).

LENTZ, et al. "Low Molecular weight Protein Apheresis and Regression of Breast Cancer", *Abstract in Japanese Society of Apheresis* 15 Supplement S31, W4-3(1996).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

U.S.S.N.: 09/699,003
Filed: October 26, 2000
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Respectfully submitted,

/ Charles Vorndran /

Charles Vorndran, Ph.D.
Reg. No. 45,315

Dated: March 27, 2008

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2151 (Telephone)
(404) 879-2160 (Fax)